Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2008
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00262860 (Phase II Pilot Study of Bortezomib), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Pilot Study of Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Who cites it
15 citing papers in PubMed, 43 citations in OpenAlex.
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.American journal of hematology · 2010Trial
- NFkB Pathway and Hodgkin Lymphoma.Biomedicines · 2022Review
- Diagnosis of Hodgkin lymphoma in the modern era.British journal of haematology · 2019Review
- Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.Blood and lymphatic cancer : targets and therapy · 2017Article
- Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Oncotarget · 2016Review
- Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.ISRN oncology · 2014Review
- Novel CD20 monoclonal antibodies for lymphoma therapy.Journal of hematology & oncology · 2012Review
- Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012Article
- Targeted therapy in lymphoma.Journal of hematology & oncology · 2010Review
- Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.Blood reviews · 2010Review
- Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?Current hematologic malignancy reports · 2010Review
- Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.International journal of clinical and experimental medicine · 2010Article
- TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.Leukemia · 2010Article
- Programmed cell death pathways and current antitumor targets.Pharmaceutical research · 2009Review
- Clinical development of novel proteasome inhibitors for cancer treatment.Expert opinion on investigational drugs · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundGiven the significant activity and tolerability of gemcitabine in patients with relapsed Hodgkin's lymphoma (HL), the critical role that nuclear factor kappa B (NF-kappaB) appears to play in the pathogenesis of this tumor, the ability of bortezomib to inhibit NF-kappaB activity, and laboratory studies suggesting synergistic antitumor effects of gemcitabine and bortezomib, we hypothesized that this combination would be efficacious in patients with relapsed or refractory HL. PATIENTS AND
methodsA total of 18 patients participated. Patients received 3-week cycles of bortezomib 1 mg/m(2) on days 1, 4, 8, and 11 plus gemcitabine 800 mg/m(2) on days 1 and 8.
resultsThe overall response rate for all patients was 22% (95% confidence interval 3% to 42%). Three patients developed grade III transaminase elevation: one was removed from the study and two had doses of gemcitabine held. Almost all patients exhibited inhibition of proteasome activity with treatment.
conclusionsThe combination of gemcitabine and bortezomib is a less active and more toxic regimen in relapsed HL than other currently available treatments. It poses a risk of severe liver toxicity and should be pursued with caution in other types of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.